Antiplatelet effect of AMP-activated protein kinase activator and its potentiation by the phosphodiesterase inhibitor dipyridamole

Biochemical Pharmacology

Volumn 86, Issue 7, 2013, Pages 914-925

  Liu, Yingqiu ^a   Oh, Seok Jeong ^a   Chang, Kyung Hwa ^a   Kim, Yoon Gyoon ^b   Lee, Moo Yeol ^a  

^a Dongguk University   (South Korea)

^b Dankook University   (South Korea)

Author keywords

AMP activated protein kinase (AMPK); Antiplatelet therapy; Platelet aggregation; Thrombosis 5 Aminoimidazole 4 carboxamide 1 d ribofuranoside (AICAR)

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ANTITHROMBOCYTIC AGENT; CYCLIC GMP; DIPYRIDAMOLE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; THROMBOCYTE AGGREGATION INHIBITION;

AMP-ACTIVATED PROTEIN KINASE (AMPK); ANTIPLATELET THERAPY; PLATELET AGGREGATION; THROMBOSIS 5-AMINOIMIDAZOLE-4-CARBOXAMIDE-1-Β-D-RIBOFURANOSIDE (AICAR);

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CYCLIC GMP; DIPYRIDAMOLE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME ACTIVATORS; MALE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84884699320     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.07.009     Document Type: Article

References (56)

1. A.D. Michelson Antiplatelet therapies for the treatment of cardiovascular disease Nature Reviews Drug Discovery 9 2010 154 169
2. P. Gresele, S. Momi, and E. Falcinelli Anti-platelet therapy: phosphodiesterase inhibitors British Journal of Clinical Pharmacology 72 2011 634 646
3. D.G. Hardie AMP-activated protein kinase as a drug target Annual Review of Pharmacology and Toxicology 47 2007 185 210
4. G.R. Steinberg, and B.E. Kemp AMPK in health and disease Physiological Reviews 89 2009 1025 1078
5. B.B. Zhang, G. Zhou, and C. Li AMPK: an emerging drug target for diabetes and the metabolic syndrome Cell Metabolism 9 2009 407 416
6. A.K. Wong, J. Howie, J.R. Petrie, and C.C. Lang AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease Clinical Science (London) 116 2009 607 620
7. M.A. Ewart, and S. Kennedy Diabetic cardiovascular disease - AMP-activated protein kinase (AMPK) as a therapeutic target Cardiovascular & Hematological Agents in Medicinal Chemistry 10 2012 190 211
8. Z.P. Chen, K.I. Mitchelhill, B.J. Michell, D. Stapleton, I. Rodriguez-Crespo, and L.A. Witters AMP-activated protein kinase phosphorylation of endothelial NO synthase FEBS Letters 443 1999 285 289 (Pubitemid 29080812)
9. Y. Zhang, T.S. Lee, E.M. Kolb, K. Sun, X. Lu, and F.M. Sladek AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stress Arteriosclerosis, Thrombosis, and Vascular Biology 26 2006 1281 1287 (Pubitemid 44305371)
10. V.A. Morrow, F. Foufelle, J.M. Connell, J.R. Petrie, G.W. Gould, and I.P. Salt Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells The Journal of Biological Chemistry 278 2003 31629 31639 (Pubitemid 37048341)
11. V. Randriamboavonjy, J. Isaak, T. Fromel, B. Viollet, B. Fisslthaler, and K.T. Preissner AMPK alpha2 subunit is involved in platelet signaling, clot retraction, and thrombus stability Blood 116 2010 2134 2140
12. I. Fleming, C. Schulz, B. Fichtlscherer, B.E. Kemp, B. Fisslthaler, and R. Busse AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets Thrombosis and Haemostasis 90 2003 863 871 (Pubitemid 37427856)
13. M.J. Sanders, Z.S. Ali, B.D. Hegarty, R. Heath, M.A. Snowden, and D. Carling Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family The Journal of Biological Chemistry 282 2007 32539 32548 (Pubitemid 350159309)
14. T. Pang, Z.S. Zhang, M. Gu, B.Y. Qiu, L.F. Yu, and P.R. Cao Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells The Journal of Biological Chemistry 283 2008 16051 16060
15. M.Y. Lee, O.N. Bae, S.M. Chung, K.T. Kang, J.Y. Lee, and J.H. Chung Enhancement of platelet aggregation and thrombus formation by arsenic in drinking water: a contributing factor to cardiovascular disease Toxicology and Applied Pharmacology 179 2002 83 88
16. M.Y. Lee, A. San Martin, P.K. Mehta, A.E. Dikalova, A.M. Garrido, and S.R. Datla Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation Arteriosclerosis, Thrombosis, and Vascular Biology 29 2009 480 487
17. A.K. Nussler, M. Glanemann, A. Schirmeier, L. Liu, and N.C. Nussler Fluorometric measurement of nitrite/nitrate by 2,3-diaminonaphthalene Nature Protocols 1 2006 2223 2226
18. K.D. Kurz, B.W. Main, and G.E. Sandusky Rat model of arterial thrombosis induced by ferric chloride Thrombosis Research 60 1990 269 280
19. A. Eckly, B. Hechler, M. Freund, M. Zerr, J.P. Cazenave, and F. Lanza Mechanisms underlying FeCl3-induced arterial thrombosis Journal of Thrombosis and Haemostasis 9 2011 779 789
20. J.M. Corton, J.G. Gillespie, S.A. Hawley, and D.G. Hardie 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? European Journal of Biochemistry 229 1995 558 565
21. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, and J. Fenyk-Melody Role of AMP-activated protein kinase in mechanism of metformin action Journal of Clinical Investigation 108 2001 1167 1174 (Pubitemid 32995375)
22. N. Henin, M.F. Vincent, and G. Van den Berghe Stimulation of rat liver AMP-activated protein kinase by AMP analogues Biochimica et Biophysica Acta 1290 1996 197 203 (Pubitemid 26184469)
23. N. Musi, T. Hayashi, N. Fujii, M.F. Hirshman, L.A. Witters, and L.J. Goodyear AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle American Journal of Physiology, Endocrinology and Metabolism 280 2001 E677 E684
24. Z. Chen, I.C. Peng, W. Sun, M.I. Su, P.H. Hsu, and Y. Fu AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633 Circulation Research 104 2009 496 505
25. M.W. Radomski, R.M. Palmer, and S. Moncada Characterization of the l-arginine:nitric oxide pathway in human platelets British Journal of Pharmacology 101 1990 325 328 (Pubitemid 20292885)
26. R.L. Jacobs, S. Lingrell, J.R. Dyck, and D.E. Vance Inhibition of hepatic phosphatidylcholine synthesis by 5-aminoimidazole-4-carboxamide-1-beta-4- ribofuranoside is independent of AMP-activated protein kinase activation The Journal of Biological Chemistry 282 2007 4516 4523 (Pubitemid 47100967)
27. J.T. Lanner, D.K. Georgiou, A. Dagnino-Acosta, A. Ainbinder, Q. Cheng, and A.D. Joshi AICAR prevents heat-induced sudden death in RyR1 mutant mice independent of AMPK activation Nature Medicine 18 2012 244 251
28. D. Meley, C. Bauvy, J.H. Houben-Weerts, P.F. Dubbelhuis, M.T. Helmond, and P. Codogno AMP-activated protein kinase and the regulation of autophagic proteolysis The Journal of Biological Chemistry 281 2006 34870 34879 (Pubitemid 46036526)
29. S. Fogarty, and D.G. Hardie Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer Biochimica et Biophysica Acta 1804 2010 581 591
30. N. Ikematsu, M.L. Dallas, F.A. Ross, R.W. Lewis, J.N. Rafferty, and J.A. David Phosphorylation of the voltage-gated potassium channel Kv2.1 by AMP-activated protein kinase regulates membrane excitability Proceedings of the National Academy of Sciences of the United States of America 108 2011 18132 18137
31. B. Cool, B. Zinker, W. Chiou, L. Kifle, N. Cao, and M. Perham Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome Cell Metabolism 3 2006 403 416 (Pubitemid 43811782)
32. K. Kolandaivelu, and D.L. Bhatt Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence Nature Reviews Cardiology 7 2010 461 467
33. I. Sakuma, Y. Akaishi, M. Fukao, Y. Makita, M.A. Makita, and T. Kobayashi Dipyridamole potentiates the anti-aggregating effect of endothelium-derived relaxing factor Thrombosis Research 12 Suppl. 1990 87 90
34. M. Foretz, S. Hebrard, J. Leclerc, E. Zarrinpashneh, M. Soty, and G. Mithieux Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state The Journal Clinical Investigation 120 2010 2355 2369
35. R.A. Miller, Q. Chu, J. Xie, M. Foretz, B. Viollet, and M.J. Birnbaum Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP Nature 494 2013 256 260
36. R. De Caterina, P. Marchetti, W. Bernini, R. Giannarelli, D. Giannessi, and R. Navalesi The direct effects of metformin on platelet function in vitro European Journal of Clinical Pharmacology 37 1989 211 213 (Pubitemid 19215467)
37. G. Formoso, E.A. De Filippis, N. Michetti, P. Di Fulvio, A. Pandolfi, and T. Bucciarelli Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects Diabetes Metabolism Research and Reviews 24 2008 231 237 (Pubitemid 351385541)
38. J.S. Sidhu, D. Cowan, J.A. Tooze, and J.C. Kaski Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease American Heart Journal 147 2004 e25
39. M.P. Khanolkar, R.H. Morris, A.W. Thomas, H. Bolusani, A.W. Roberts, and J. Geen Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus - an effect probably mediated by direct platelet PPARgamma activation Atherosclerosis 197 2008 718 724 (Pubitemid 351417869)
40. D. Li, K. Chen, N. Sinha, X. Zhang, Y. Wang, and A.K. Sinha The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation Cardiovascular Research 65 2005 907 912 (Pubitemid 40253577)
41. T. Ishizuka, S. Itaya, H. Wada, M. Ishizawa, M. Kimura, and K. Kajita Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism Diabetes 47 1998 1494 1500 (Pubitemid 28396955)
42. P.F. Bodary, F.B. Vargas, S.A. King, K.L. Jongeward, K.J. Wickenheiser, and D.T. Eitzman Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance Journal of Thrombosis and Haemostasis 3 2005 2149 2153 (Pubitemid 41727189)
43. J.J. O'Brien, D.M. Ray, S.L. Spinelli, N. Blumberg, M.B. Taubman, and C.W. Francis The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARgamma ligands Prostaglandins & Other Lipid Mediators 82 2007 68 76 (Pubitemid 44880164)
44. W.J. Lee, K.H. Song, E.H. Koh, J.C. Won, H.S. Kim, and H.S. Park Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle Biochemical and Biophysical Research Communications 332 2005 885 891
45. T.T. Hien, W.K. Oh, P.H. Nguyen, S.J. Oh, M.Y. Lee, and Kang K.W. Nectandrin B activates endothelial nitric-oxide synthase phosphorylation in endothelial cells: role of the AMP-activated protein kinase/estrogen receptor alpha/phosphatidylinositol 3-kinase/Akt pathway Molecular Pharmacology 80 2011 1166 1178
46. D.J. Cuthbertson, J.A. Babraj, K.J. Mustard, M.C. Towler, K.A. Green, and H. Wackerhage 5-Aminoimidazole-4-carboxamide 1-beta-d-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men Diabetes 56 2007 2078 2084 (Pubitemid 47195820)
47. A.V. Kwiatkowski, F.B. Gertler, and J.J. Loureiro Function and regulation of Ena/VASP proteins Trends in Cell Biology 13 2003 386 392 (Pubitemid 36776716)
48. H. Seidel, M.M. Rahman, and R.E. Scharf Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives Hamostaseologie 31 2011 41 51
49. D.A. Bullough, C. Zhang, A. Montag, K.M. Mullane, and M.A. Young Adenosine-mediated inhibition of platelet aggregation by acadesine A novel antithrombotic mechanism in vitro and in vivo Journal of Clinical Investigation 94 1994 1524 1532
50. M.A. Young, C. Henry, S. Wong, D. Bullough, and K. Mullane Acadesine reduces the frequency of coronary artery reocclusion following rt-PA induced thrombolysis in the dog Thrombosis and Haemostasis 74 1995 1348 1352
51. J.M. Gibbins, and M.P. Mahaut-Smith Platelets and megakaryocytes 2004 Humana Press Totowa, N.J.
52. P. Gresele, J. Arnout, H. Deckmyn, and J. Vermylen Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity Thrombosis and Haemostasis 55 1986 12 18 (Pubitemid 16117223)
53. P. Gresele, C. Zoja, H. Deckmyn, J. Arnout, J. Vermylen, and M. Verstraete Dipyridamole inhibits platelet aggregation in whole blood Thrombosis and Haemostasis 50 1983 852 856 (Pubitemid 14218224)
54. J.E. Freedman, J. Loscalzo, M.R. Barnard, C. Alpert, J.F. Keaney, and A.D. Michelson Nitric oxide released from activated platelets inhibits platelet recruitment The Journal of Clinical Investigation 100 1997 350 356 (Pubitemid 27349081)
55. C. Tymvios, C. Moore, S. Jones, A. Solomon, D. Sanz-Rosa, and M. Emerson Platelet aggregation responses are critically regulated in vivo by endogenous nitric oxide but not by endothelial nitric oxide synthase British Journal of Pharmacology 158 2009 1735 1742
56. C. Moore, D. Sanz-Rosa, and M. Emerson Distinct role and location of the endothelial isoform of nitric oxide synthase in regulating platelet aggregation in males and females in vivo European Journal of Pharmacology 651 2011 152 158